Global collaboration with TG Therapeutic (NSDAQ: TGTX).
22nd program of "Le Monde de Demain" dedicated to biotechnologies.
Nicolas Fischer, CEO introduces Light Chain Bioscience | Novimmune SA.
Edesa Biotech enrolls First Patient in COVID-19 Study of NI-0101 / EB05 (TLR4 anytibody).
Light Chain Bioscience has entered into two research collaborations and worldwide licensing agreements with Discoveric bio group.
